Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.
| Revenue (TTM) | $280.75M |
| Gross Profit (TTM) | $247.69M |
| EBITDA | $-186.23M |
| Operating Margin | -42.60% |
| Return on Equity | -78.00% |
| Return on Assets | -24.60% |
| Revenue/Share (TTM) | $4.12 |
| Book Value | $1.27 |
| Price-to-Book | 82.96 |
| Price-to-Sales (TTM) | 25.93 |
| EV/Revenue | 25.25 |
| EV/EBITDA | -12.65 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 79.60% |
| Shares Outstanding | $69.33M |
| Float | $56.43M |
| % Insiders | 0.69% |
| % Institutions | 114.26% |
Volatility is currently expanding
AstraZeneca recently made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, according to people familiar with the matter, a deal that would expand its portfolio of rare disease treatments.
-- Expanded guidance based on additional evidence demonstrating the benefits of IMCIVREE in adults living with Bardet-Biedl syndrome -- BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the National Institute for Health and Care Excellence (NICE) has issued a positive guidance for IMCIVREE® (setmelanotide) to include adults living with genetically confirmed Bardet-Biedl syndrome (BBS).
Rhythm Pharmaceuticals NASDAQ: RYTM reported third-quarter global net product sales of $92.1 million, up 29% sequentially, as the company cited a strong early U.S. launch for IMCIVREE in acquired hypothalamic obesity, or acquired HO. The company also outlined plans to advance bivamelagon into Phase III studies for acquired HO and Prader-Willi syndrome, while expanding its international commercial footprint.
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.82 per share a year ago.
-- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026 net product revenue from global sales of IMCIVREE of $92.1 million, an increase of 29% from the prior quarter -- -- Commercial launch of IMCIVREE in Japan for patients with acquired HO underway -- -- Bivamelagon to advance into pivotal development in Prader-Willi syndrome --
-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed payments totaling $350 million over four years --
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update.
-- Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance drug price list -- -- IMCIVREE is the first approved therapy in Japan for patients living with acquired hypothalamic obesity --
Rhythm Pharmaceuticals (RYTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RYTM and any ticker you trade — then tracks every position and per-strategy win rate.
